Based on the experience conducted in the “Seminar on early access in oncology” (28 and 29 June 2018) – and the subsequent publication of the article “Early Access in oncology: why is it needed?”, Apolone et al, 2019, GRHTA – all oncological and oncohaematological drugs that obtained the full or conditional assessment of innovativeness from AIFA (time period March 2017 – September 2019) were evaluated, in order to verify their “retrospective merit” for access to the early access.
SAVE THE DATE: "Mogliano Veneto Seminar" - Edition 7 - Mogliano Veneto, September 26th and 27th 2024
